Rare diseases
Investigational molecules
Locations
Back to Poland113 clinical trials in Koszalin, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PolandBadaniaKliniczne.pl(opens in a new tab)Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer
PolandStudy of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery
PolandStudy Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer
PolandStudy of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer
PolandStudy of Pembrolizumab and Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer
PolandStudy to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment
PolandStudy of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy
PolandStudy on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
PolandStudy of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer
PolandStudy of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
PolandStudy of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer
PolandStudy of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer
PolandThe busiest research cities in the country
What the registry says about research in the country
Innovative research focusing on bladder cancer and prostate cancer treatments, including combination therapies with immunological agents and targeted treatments.
Studies evaluating durvalumab, BCG combinations, and hormone therapy approaches for improved patient outcomes.
Advanced studies in gastric cancer and gastroesophageal junction cancers, focusing on targeted therapies and immunotherapy combinations.
Investigating trastuzumab deruxtecan and other innovative treatment combinations for metastatic disease.
Comprehensive research in non-small cell lung cancer, exploring novel drug combinations and immunotherapy approaches.
Evaluating new therapeutic options including pembrolizumab combinations and investigational agents.
Pioneering research in advanced breast cancer treatment, particularly focusing on hormone receptor-positive, HER2-negative disease.
Studies exploring new treatment combinations with CDK4/6 inhibitors and hormone therapy.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
